How many patents mention targeting Phosphatidylserine and how many more are there out there? or en route? a few published online very recently ... further below on each section will include some posts, interesting Greg Lemke goes to UTSWM at that time and have there been collaborations all along ??
1) Salk Institute / Kolltan Inventors: Greg E. Lemke, Lawrence C. Fritz, Benedikt VOLLRATH, Carla V. Rothlin
4) Institut National De La Sante Et De La Recherche Medicale (Inserm) Inventors: Ali Amara, Laurent Meertens
Publication date Aug 29, 2013 Filing date Feb 20, 2013 Priority date Feb 21, 2012
****************** 1 ********************
Regulating the interaction between tam ligands and lipid membranes with exposed phosphatidyl serine
Publication number US20170129947 A1 Publication type Application Application number US 15/270,813
Publication date 11 May 2017 Filing date 20 Sep 2016 Priority date 25 Jul 2012
Also published as CA2879542A1, EP2877211A1, EP2877211A4, EP3184121A2, US20150164800, WO2014018535A1, Less «
Inventors: Greg E. Lemke, Lawrence C. Fritz, Benedikt VOLLRATH, Carla V. Rothlin
Original Assignee: Salk Institute For Biological Studies, Kolltan Pharmaceuticals, Inc.
US 20170129947 A1 Abstract The present disclosure provides methods for modulating the interaction between a TAM ligand and a lipid membrane containing phosphatidyl serine (PtdSer). In one example, such methods use a TAM receptor agonist having a PtdSer-containing lipid bilayer membrane with Gas6 and/or Protein S bound to the membrane to activate signaling from one or more TAM receptors and treat an autoimmune disease. In another example, methods are provided for treating a subject with a pathological condition characterized by overactivation of TAM signaling and/or reduction in Type I IFN response, such as infection by an enveloped virus, by use of agents that decrease the interaction between a TAM ligand and PtdSer. Also provided are methods for classifying a virus as susceptible to anti-TAM therapy. Methods of identifying an agent that blocks virus infectivity are also provided.
Read the post chain, especially the one before this post AND after you read it SLOWLY, then read this specific post below SLOWLY and finally, let it all sink in that Greg Lemke is coming in house to UTSWM with Dr. Rolf Brekken as host! Something big is being set up here ... http://investorshub.advfn.com/boards/read_msg.aspx?message_id=117271035
This is about showing some background and ties to Carla Vanina Rothlin <> Greg Lemke, because Kolltan buys out the IP patent rights of Xertrios/Greg Lemke..etc and if you have been following these posts along you should know this but just for a refresher below and if you are just joining this gets interesting because Greg Lemke is welcomed into UTSWM next month with Dr. Rolf Brekken as host.
Abstract The disclosure relates to the recombinant Gla domain proteins and their use targeting phosphatidylserine (PtdS) moieties on the surface of cells, particularly those expressing elevated levels of PtdS, such as cells undergoing apoptosis.
Publication number US9694048 B2 Publication type Grant Application number US 14/773,068 PCT number PCT/US2014/026237
Publication date Jul 4, 2017 Filing date Mar 13, 2014 Priority date Mar 15, 2013
Also published as CA2905972A1, CA2905986A1, CN105008397A, CN105164152A, EP2970429A1, EP2970429A4, EP2970442A1, EP2970442A4, US20160008482, US20160106806, WO2014151535A1, WO2014151683A1, WO2014151683A8, Less «
Title: TUMOR IMMUNITY Document Type and Number: United States Patent Application 20170224793 Kind Code: A1
Abstract: Disclosed herein are materials and methods for treating cancer. In particular, compositions for stimulating tumor immunity through modulation of MFG-E8 are provided.
Tam receptors as virus entry cofactors WO 2013124324 A1 Abstract The present invention concerns the use of an inhibitor of an interaction between phosphatidylserine and a TAM receptor for preventing or treating a virus entry cofactors, in particular phosphatidylserine harboring virus infection such as flavivirus infection.
The TIM and TAM Families of Phosphatidylserine Receptors Mediate Dengue Virus Entry
Laurent Meertens · Xavier Carnec · Manuel Perera Lecoin · Rasika Ramdasi · Ali Amara
Abstract: Dengue viruses (DVs) are responsible for the most medically relevant arboviral diseases. However, the molecular interactions mediating DV entry are poorly understood. We determined that TIM and TAM proteins, two receptor families that mediate the phosphatidylserine (PtdSer)-dependent phagocytic removal of apoptotic cells, serve as DV entry factors. Cells poorly susceptible to DV are robustly infected after ectopic expression of TIM or TAM receptors. Conversely, DV infection of susceptible... https://www.researchgate.net/scientific-contributions/2001916760_Laurent_Meertens
Market Data 
Markets 
AI
